No Data
No Data
Hong Kong stock unusual movement | Pharmaron (03759) increase expands to 20%. Biomedical investment and financing are expected to recover as the company's new signed order amount in the first half of the year exceeds 15%.
Pharmaron (03759) has expanded its gain to 20%, as of the deadline, it has increased by 19.5%, closing at 19 Hong Kong dollars, with a turnover of 0.18 billion Hong Kong dollars.
Biomedical sector showing strong performance, Pharmaron (03759) rose by 14.97%. Institutions believe there is still room for further increase in sector valuation.
Golden Finance News | The biomedical sector is showing strong performance, with Pharmaron (03759) up 14.97%, Remegen (09995) up 13.59%, Tigermed (03347) up 12.58%, Wuxi Bio (02269) up 11.79%, Wuxi Apptec (02359) up 10.56%, Akeso (09926) up 8.92%. In terms of news, Guoyuan International believes that the main reason for the outperformance of the pharmaceutical sector in this round of large gains is due to the deeper decline in the pharmaceutical sector in the previous period (as of September 23, MSCI China Meheco Group Index has fallen 23% year-to-date), sector.
Hong Kong stock market anomaly | CRO concept stocks lead the gains. The US Biological Safety Act is unlikely to be implemented this year, and medical investment and financing are expected to recover rapidly in the rate-cut cycle.
CRO concept stocks performed well in the morning trading session, as of the time of publication, Wuxi AppTec (02359) rose by 7.32% to HKD 64.55; Tigermed (03347) rose by 7.02% to HKD 51.05; Wuxi Bio (02269) rose by 6.72% to HKD 20; Pharmaron (03759) rose by 6.67% to HKD 16.96.
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
Trending Industry Today: TIGERMED Leads Gains In CRO Stocks
Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks